Glycine

Glycine

SCHEMBL6162319

CCl.NCC(=O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL28749082 0.93 GLRA1 (0.67)
Glycine SCHEMBL2869784 0.90 GLRA1 (0.62)
Glycine SCHEMBL3384608 0.88
Glycine SCHEMBL2340760 0.88
Glycine SCHEMBL246859 0.88 GLRA1 (0.83)
Glycine SCHEMBL474856 0.88
Glycine SCHEMBL28317820 0.88
Glycine SCHEMBL2299139 0.88
Glycine SCHEMBL391786 0.88 GLRA1 (1.00)
Glycine SCHEMBL3640989 0.88 GLRA1 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024114730-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER 微境生物医药科技(上海)有限公司 2024-06-06 WO disclosed
WO-2024061172-A1 PROLYL HYDROXYLASE INHIBITOR AND USE THEREOF 苏中药业集团股份有限公司 2024-03-28 WO disclosed
CN-114230466-A Dichloroacetic acid coupled diphenylethane compound, preparation method and application thereof 上海华理生物医药股份有限公司 2022-03-25 CN disclosed
US-20210071036-A1 POLISHING COMPOSITION FUJIMI INCORPORATED (JP) 2021-03-11 US disclosed
WO-2021033766-A1 LITHOCHOLIC ACID DERIVATIVE HAVING VITAMIN D ACTIVITY 国立大学法人お茶の水女子大学 2021-02-25 WO disclosed
US-10907073-B2 Polishing composition FUJIMI INCORPORATED 2021-02-02 US disclosed
CN-105085429-B Aromatic heterocyclic derivative and application thereof in medicines 广东东阳光药业有限公司 2019-12-10 CN disclosed
US-20190352536-A1 POLISHING COMPOSITION FUJIMI INCORPORATED (JP) 2019-11-21 US disclosed
WO-2019189419-A1 ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE 持田製薬株式会社 2019-10-03 WO disclosed
EP-2881384-B1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO LTD (JP) 2018-05-30 EP disclosed
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-06-25 US disclosed
EP-2881384-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Taisho Pharmaceutical Co., Ltd. (JP) 2015-06-10 EP disclosed
US-20140117280-A1 OXYGEN ABSORBER MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2014-05-01 US disclosed
EP-2711077-A1 OXYGEN ABSORBER Mitsubishi Gas Chemical Company, Inc. (JP) 2014-03-26 EP disclosed
EP-1178969-B1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS BLACK JAMES FOUNDATION (GB) 2005-07-13 EP disclosed
US-6479531-B1 Gastrin and cholecystokinin receptor ligands JAMES BLACK FOUNDATION LIMITED (GB) 2002-11-12 US disclosed
EP-1178969-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2002-02-13 EP disclosed
WO-2000027823-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2000-05-18 WO disclosed
EP-0308319-B1 4-PIPERIDINECARBOXAMIDE DERIVATIVES MITSUBISHI KASEI CORPORATION (JP) 1993-03-10 EP disclosed
EP-0308319-A2 4-Piperidinecarboxamide derivatives MITSUBISHI KASEI CORPORATION (JP) 1989-03-22 EP disclosed